Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Cappelli

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Seminars in Arthritis and Rheumatism|June 20, 2025
Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysisLaura C Cappelli, Jamie Perin, Scott Zeger, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Corticosteroid-resistant immune-related adverse events: a systematic reviewEveline Daetwyler, Till Wallrabenstein, David König, et al.
Human Pathology|July 8, 2019
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanomaErika F Rodriguez, Evan Lipson, Karthik Suresh, et al.
BMC Rheumatology|August 9, 2020
Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gapsLaura C Cappelli, Suzanne M Grieb, Ami A Shah, et al.
The Journal of Dermatological Treatment|March 3, 2021
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatosesThomas K Le, Subuhi Kaul, Laura C Cappelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 15, 2017
Two Cases of Sinusitis Induced by Immune Checkpoint InhibitionEric Dein, William Sharfman, Jean Kim, et al.
Journal of Cancer Research and Clinical Oncology|September 14, 2022
Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity teamChristopher Fan, Ahyoung Kim, Sean Li, et al.
The Journal of Rheumatology|February 15, 2024
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis RegistryDimitrios A Pappas, Jacqueline O'Brien, Page C Moore, et al.
The Journal of Rheumatology|January 15, 2026
Hip osteoarthritis is not a risk factor for immune checkpoint inhibitor-induced inflammatory arthritisRebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, et al.
The Journal of Rheumatology|April 15, 2026
Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory ArthritisRebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Seminars in Arthritis and Rheumatism|June 20, 2025
Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysisLaura C Cappelli, Jamie Perin, Scott Zeger, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Corticosteroid-resistant immune-related adverse events: a systematic reviewEveline Daetwyler, Till Wallrabenstein, David König, et al.
Human Pathology|July 8, 2019
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanomaErika F Rodriguez, Evan Lipson, Karthik Suresh, et al.
BMC Rheumatology|August 9, 2020
Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gapsLaura C Cappelli, Suzanne M Grieb, Ami A Shah, et al.
The Journal of Dermatological Treatment|March 3, 2021
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatosesThomas K Le, Subuhi Kaul, Laura C Cappelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 15, 2017
Two Cases of Sinusitis Induced by Immune Checkpoint InhibitionEric Dein, William Sharfman, Jean Kim, et al.
Journal of Cancer Research and Clinical Oncology|September 14, 2022
Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity teamChristopher Fan, Ahyoung Kim, Sean Li, et al.
The Journal of Rheumatology|February 15, 2024
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis RegistryDimitrios A Pappas, Jacqueline O'Brien, Page C Moore, et al.
The Journal of Rheumatology|January 15, 2026
Hip osteoarthritis is not a risk factor for immune checkpoint inhibitor-induced inflammatory arthritisRebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, et al.
The Journal of Rheumatology|April 15, 2026
Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory ArthritisRebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, et al.
Pageof 6